Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palifermin to reduce severity and incidence of mucositis in stem cell transplant patients
2006-001923-20Phase 3Terminated
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Mar 2007
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, single-arm trial of palifermin in mucositis, non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL) and 5 more, sponsored by IRCCS Ospedale San Raffaele. Primary endpoints: Incidence of severe mucositis and Duration of severe mucositis. Started Mar 2007; status: terminated.
02
Drugs
palifermin
03
Conditions
mucositisnon-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)chronic myelogenous leukemia (CML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2006-001923-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001923-20.